Treatment

11 to 13 + 6 weeks Genetic Scan

The 11 to 13+6 weeks genetic scan, also known as the first-trimester screening, combines a blood test with an ultrasound to assess the risk of certain genetic conditions, like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). 

Here's a more detailed explanation:

• What it is:

  This screening is a combination of a maternal blood test and a nuchal translucency test (ultrasound) performed between 11 and 13+6 weeks of pregnancy. 

• Purpose:

  The primary goal is to assess the risk of chromosomal abnormalities in the fetus, such as Down's syndrome, Edwards' syndrome, and Patau's syndrome. 

• How it works:

  • Blood Test: Measures the levels of two substances (free beta-hCG and PAPP-A) in the mother's blood. 
  • Nuchal Translucency Test (Ultrasound): Measures the thickness of the fluid-filled space at the back of the fetus's neck. 

• What it checks for:

  • Increased risk of chromosomal abnormalities: A thickened nuchal translucency or abnormal blood test results can indicate an increased risk of Down's syndrome, Edwards' syndrome, or Patau's syndrome. 
  • Other potential issues: The ultrasound can also help identify other potential problems, such as fetal heart abnormalities. 

About Us

We are Ready to Help Improve Your Treatment.

Lorem ipsum dolor sit amet consectetur adipisicing elit. Quaerat deleniti amet at atque sequi quibusdam cumque itaque repudiandae temporibus, eius nam mollitia voluptas maxime veniam necessitatibus saepe in ab? Repellat!